Published by
Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics
PHILADELPHIA —Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced today that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: […]
